Skip to main content
Premium Trial:

Request an Annual Quote

Three RNAi-Related Patent Applications Published by the USPTO: May 20, 2005

Premium

Title: Genes Required for Viability And/Or Reproduction in C. elegans and Their Use in the Development of Anti-Nematode Agents.

Number: 20050101773.

Filed: Sept. 8, 2003. PCT Filed Nov. 9, 2001.

Lead Inventor: : Chris Echeverri, Cenix Bioscience.

"The … invention relates to several C. elegans genes and gene products identified by means of RNA-mediated interference as required for the viability, growth, or reproduction of nematodes and to functional orthologues of said genes and gene products found in other nematode species, including all biologically-active derivatives thereof," the patent application's abstract states.

"The invention also comprises the use of said genes and gene products in the development of anti-nematode or other pesticidal agents and in methods for diagnosis and treatment of diseases associated with the infection or presence of nematodes."


Title: RNA Interference Pathway Genes as Tools for Targeted Genetic Interference.

Number: 20050100913.

Filed: Aug. 20, 2003.

Lead Inventor: Craig Mello, University of Massachusetts Medical School.

According to the patent application's abstract, the invention comprises "genes involved in double-stranded RNA interference [used] to investigate the RNAi pathway. The genes and their products are also useful for modulating RNAi pathway activity," the abstract adds.


Title: Method and Medicament for Inhibiting the Expression of a Given Gene.

Number: 20050100907.

Filed: July 2, 2003.

Lead Inventor: Roland Kreutzer, Ribopharma (Alnylam Europe).

"The invention relates to an isolated RNA that mediates RNA interference of an mRNA to which it corresponds and a method of mediating RNA interference of mRNA of a gene in a cell or organism using the isolated RNA," the patent application's abstract states.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.